Fig. 5 | Scientific Reports

Fig. 5

From: Screening of the Pandemic Response Box library identified promising compound candidate drug combinations against extensively drug-resistant Acinetobacter baumannii

Fig. 5

Time-kill curve. (A) A. baumannii QS17-1084 incubated without antibiotic (growth control), with MUT056399, brilacidin, MUT056399:brilacidin (ratio 1:2), and MUT056399:brilacidin (ratio 4:1). (B) A. baumannii 5075 incubated without antibiotic (growth control), with MUT056399, eravacycline: MUT056399:eravacycline (ratio 3:1), and MUT056399 : eravacycline (ratio 1:2). *P < 0.05 was analyzed by Dunnett's multiple comparisons test to compare between drug combination (MUT056399 and brilacidin at the ratio 1:2 for A. baumannii QS17-1084; and MUT056399 and eravacycline at ratio 1:2 for A. baumannii 5075) versus other tested compounds and growth control.

Back to article page